carnitine has been researched along with Nervous System Diseases in 21 studies
Nervous System Diseases: Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carnitine levels in CSF were 1/10 compared with serum in normal febrile children." | 5.30 | CSF levels of carnitine in children with meningitis, neurologic disorders, acute gastroenteritis, and seizure. ( Gruener, N; Lerner, A; Shinawi, M, 1998) |
| "These data on disease progression will be useful in future studies using the canine model for therapeutic intervention studies." | 1.72 | Characterization of neurological disease progression in a canine model of CLN5 neuronal ceroid lipofuscinosis. ( Coates, JR; Jensen, CA; Katz, ML; Kick, GR; Meiman, EJ, 2022) |
| "Carnitine levels in CSF were 1/10 compared with serum in normal febrile children." | 1.30 | CSF levels of carnitine in children with meningitis, neurologic disorders, acute gastroenteritis, and seizure. ( Gruener, N; Lerner, A; Shinawi, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Rücklová, K | 1 |
| Hrubá, E | 1 |
| Pavlíková, M | 1 |
| Hanák, P | 1 |
| Farolfi, M | 1 |
| Chrastina, P | 1 |
| Vlášková, H | 1 |
| Kousal, B | 1 |
| Smolka, V | 1 |
| Foltenová, H | 1 |
| Adam, T | 1 |
| Friedecký, D | 1 |
| Ješina, P | 1 |
| Zeman, J | 1 |
| Kožich, V | 1 |
| Honzík, T | 1 |
| Meiman, EJ | 1 |
| Kick, GR | 1 |
| Jensen, CA | 1 |
| Coates, JR | 1 |
| Katz, ML | 1 |
| Praveenraj, SS | 1 |
| Sonali, S | 1 |
| Anand, N | 1 |
| Tousif, HA | 1 |
| Vichitra, C | 1 |
| Kalyan, M | 1 |
| Kanna, PV | 1 |
| Chandana, KA | 1 |
| Shasthara, P | 1 |
| Mahalakshmi, AM | 1 |
| Yang, J | 1 |
| Pandi-Perumal, SR | 1 |
| Sakharkar, MK | 1 |
| Chidambaram, SB | 1 |
| Nakamichi, N | 1 |
| Kato, Y | 1 |
| Gillingham, MB | 1 |
| Heitner, SB | 1 |
| Martin, J | 1 |
| Rose, S | 1 |
| Goldstein, A | 1 |
| El-Gharbawy, AH | 1 |
| Deward, S | 1 |
| Lasarev, MR | 1 |
| Pollaro, J | 1 |
| DeLany, JP | 1 |
| Burchill, LJ | 1 |
| Goodpaster, B | 1 |
| Shoemaker, J | 1 |
| Matern, D | 1 |
| Harding, CO | 1 |
| Vockley, J | 1 |
| Haglind, CB | 1 |
| Nordenström, A | 1 |
| Ask, S | 1 |
| von Döbeln, U | 1 |
| Gustafsson, J | 1 |
| Stenlid, MH | 1 |
| Schobersberger, W | 1 |
| Dünnwald, T | 1 |
| Gmeiner, G | 1 |
| Blank, C | 1 |
| Yamamoto, Y | 1 |
| Matsui, N | 1 |
| Hiramatsu, Y | 1 |
| Miyazaki, Y | 1 |
| Nodera, H | 1 |
| Izumi, Y | 1 |
| Takashima, H | 1 |
| Kaji, R | 1 |
| Jones, LL | 1 |
| McDonald, DA | 1 |
| Borum, PR | 1 |
| Park, HD | 1 |
| Kim, SR | 1 |
| Ki, CS | 1 |
| Lee, SY | 1 |
| Chang, YS | 1 |
| Jin, DK | 1 |
| Park, WS | 1 |
| Malaguarnera, M | 1 |
| Bähr, O | 1 |
| Mader, I | 1 |
| Zschocke, J | 1 |
| Dichgans, J | 1 |
| Schulz, JB | 1 |
| Mühlhausen, C | 1 |
| Hoffmann, GF | 1 |
| Strauss, KA | 1 |
| Kölker, S | 1 |
| Okun, JG | 1 |
| Greenberg, CR | 1 |
| Naughten, ER | 1 |
| Ullrich, K | 1 |
| Gordon, N | 1 |
| Merinero, B | 1 |
| Pérez-Cerdá, C | 1 |
| Ruiz Sala, P | 1 |
| Ferrer, I | 1 |
| García, MJ | 1 |
| Martínez Pardo, M | 1 |
| Belanger-Quintana, A | 1 |
| de la Mota, JL | 1 |
| Martin-Hernández, E | 1 |
| Vianey-Saban, C | 1 |
| Bischoff, C | 1 |
| Gregersen, N | 1 |
| Ugarte, M | 1 |
| López-Laso, E | 1 |
| García-Villoria, J | 1 |
| Martín, E | 1 |
| Duque, P | 1 |
| Cano, A | 1 |
| Ribes, A | 1 |
| Ozand, PT | 1 |
| Rashed, M | 1 |
| Gascon, GG | 1 |
| al Odaib, A | 1 |
| Shums, A | 1 |
| Nester, M | 1 |
| Brismar, J | 1 |
| Walter, JH | 1 |
| Wraith, JE | 1 |
| Cleary, MA | 1 |
| Shinawi, M | 1 |
| Gruener, N | 1 |
| Lerner, A | 1 |
| Matsuoka, M | 1 |
| Igisu, H | 1 |
| Kohriyama, K | 1 |
| Inoue, N | 1 |
| Dionisi Vici, C | 1 |
| Burlina, AB | 1 |
| Bertini, E | 1 |
| Bachmann, C | 1 |
| Mazziotta, MR | 1 |
| Zacchello, F | 1 |
| Sabetta, G | 1 |
| Hale, DE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorders[NCT01379625] | Phase 2 | 32 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Phase 2A/2B Placebo-controlled Randomised Clinical Trial to Test the Ability of Triheptanoin to Protect Primary Airway Epithelial Cells Obtained From Participants With Ataxia-telangiectasia Against Death Induced by Glucose Deprivation[NCT04513002] | Phase 2 | 30 participants (Actual) | Interventional | 2022-03-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in resting ejection fraction over 4 month treatment period (NCT01379625)
Timeframe: 4 months
| Intervention | percent (Mean) |
|---|---|
| Medium Chain Triglyceride (MCT) | -1.91 |
| Triheptanoin | 2.14 |
Total energy expenditure will be measured by doubly labeled water and resting energy expenditure will be measured by indirect calorimetry at baseline and again after 4 months of either MCT or trihpetanoin treatment. (NCT01379625)
Timeframe: change from baseline after 4 months of treatment
| Intervention | kcal/day (Mean) |
|---|---|
| Medium Chain Triglyceride (MCT) | -73 |
| Triheptanoin | 107 |
Subjects will complete a submaximal treadmill exercise study at baseline. Exercise heart heart, ventilation and perceived exertion will be measured. Subjects will be randomized to MCT or triheptanoin supplementation for 4 months. At the end of treatment, the exercise test will be repeated keeping work performed constant. Change in exercise heart rate, ventilation and exertion will be compared between groups. (NCT01379625)
Timeframe: change from baseline to 4 months of treatment
| Intervention | beats per minute (Mean) |
|---|---|
| Medium Chain Triglyceride (MCT) | -0.1 |
| Triheptanoin | -12.6 |
6 reviews available for carnitine and Nervous System Diseases
| Article | Year |
|---|---|
The Role of a Gut Microbial-Derived Metabolite, Trimethylamine N-Oxide (TMAO), in Neurological Disorders.
Topics: Betaine; Carnitine; Choline; Flavins; Gastrointestinal Microbiome; Humans; Inflammasomes; Lyases; Me | 2022 |
Physiological Roles of Carnitine/Organic Cation Transporter OCTN1/SLC22A4 in Neural Cells.
Topics: Animals; Carnitine; Humans; Nervous System Diseases; Neural Stem Cells; Neurons; Organic Cation Tran | 2017 |
Story behind meldonium-from pharmacology to performance enhancement: a narrative review.
Topics: Athletes; Athletic Performance; Cardiovascular Diseases; Carnitine; Doping in Sports; Humans; Metabo | 2017 |
Acylcarnitines: role in brain.
Topics: Acetylcarnitine; Animals; Antioxidants; Brain; Carnitine; Energy Metabolism; Fatty Acids; Nerve Grow | 2010 |
Carnitine derivatives: clinical usefulness.
Topics: Acetylcarnitine; Cardiotonic Agents; Cardiovascular Diseases; Carnitine; Cognition Disorders; Depres | 2012 |
Maintenance treatment of glutaryl-CoA dehydrogenase deficiency.
Topics: Amino Acid Metabolism, Inborn Errors; Animals; Antioxidants; Carnitine; Glutaryl-CoA Dehydrogenase; | 2004 |
1 trial available for carnitine and Nervous System Diseases
| Article | Year |
|---|---|
Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Adolescent; Adult; Caprylates; Cardiomyopathies; Carnitine; Chil | 2017 |
Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Adolescent; Adult; Caprylates; Cardiomyopathies; Carnitine; Chil | 2017 |
Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Adolescent; Adult; Caprylates; Cardiomyopathies; Carnitine; Chil | 2017 |
Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Adolescent; Adult; Caprylates; Cardiomyopathies; Carnitine; Chil | 2017 |
14 other studies available for carnitine and Nervous System Diseases
| Article | Year |
|---|---|
Impact of Newborn Screening and Early Dietary Management on Clinical Outcome of Patients with Long Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency and Medium Chain Acyl-CoA Dehydrogenase Deficiency-A Retrospective Nationwide Study.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Acyl-CoA Dehydrogenase; Cardiomyopathies; Carnitine; Child; Child, | 2021 |
Characterization of neurological disease progression in a canine model of CLN5 neuronal ceroid lipofuscinosis.
Topics: Animals; Atrophy; Carnitine; Disease Progression; Dogs; Homozygote; Nervous System Diseases; Neurona | 2022 |
Increased and early lipolysis in children with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency during fast.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Age Factors; Biomarkers; Blood Glucose; Calorimetry, Indirect; Car | 2015 |
Mitochondrial trifunctional protein deficiency: an adult patient with similar progress to Charcot-Marie-Tooth disease.
Topics: Biomarkers; Cardiomyopathies; Carnitine; Charcot-Marie-Tooth Disease; Diagnosis, Differential; Disea | 2017 |
Two novel HADHB gene mutations in a Korean patient with mitochondrial trifunctional protein deficiency.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Cardiomyopathies; Carnitine; DNA Mutational Analysis; Humans; Infa | 2009 |
Adult onset glutaric aciduria type I presenting with a leukoencephalopathy.
Topics: Adult; Amino Acid Metabolism, Inborn Errors; Brain; Carnitine; Electroencephalography; Electrophores | 2002 |
Acyl-CoA dehydrogenase deficiency: varieties with neurological involvement.
Topics: Acyl-CoA Dehydrogenase; Carnitine; Child; Child, Preschool; Chromosome Aberrations; Developmental Di | 2005 |
Persistent increase of plasma butyryl/isobutyrylcarnitine concentrations as marker of SCAD defect and ethylmalonic encephalopathy.
Topics: Brain Diseases; Butyryl-CoA Dehydrogenase; Carnitine; Humans; Malonates; Mitochondrial Proteins; Ner | 2006 |
Classic and late-onset neurological disease in two siblings with glutaryl-CoA dehydrogenase deficiency.
Topics: Adolescent; Amino Acid Metabolism, Inborn Errors; Carnitine; Female; Glutaryl-CoA Dehydrogenase; Hum | 2007 |
3-Ketothiolase deficiency: a review and four new patients with neurologic symptoms.
Topics: Acetyl-CoA C-Acyltransferase; Brain; Carnitine; Child, Preschool; Electroencephalography; Female; Fi | 1994 |
Absence of acidosis in the initial presentation of propionic acidaemia.
Topics: Acidosis; Amino Acid Metabolism, Inborn Errors; Ammonia; Benzoates; Benzoic Acid; Carnitine; Food Pr | 1995 |
CSF levels of carnitine in children with meningitis, neurologic disorders, acute gastroenteritis, and seizure.
Topics: Adolescent; Carnitine; Child; Child, Preschool; Female; Fever; Gastroenteritis; Humans; Infant; Infa | 1998 |
Suppression of neurotoxicity of ammonia by L-carnitine.
Topics: Ammonia; Animals; Behavior, Animal; Brain Chemistry; Carnitine; Energy Metabolism; Male; Mice; Mice, | 1991 |
Progressive neuropathy and recurrent myoglobinuria in a child with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Biopsy; Carnitine; Child; Combined Modality Therapy; Dietary Fats; | 1991 |